SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 23, 2016

Primary Completion Date

August 27, 2021

Study Completion Date

August 27, 2021

Conditions

Metastatic Malignant Neoplasm in the BrainMetastatic Malignant Neoplasm in the SpineStage IV Skin Melanoma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

RADIATION

Stereotactic Radiosurgery

Undergo stereotactic radiosurgery

Trial Locations (1)

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

All Listed Sponsors

collaborator

Accuray Incorporated

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT02716948 - SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine | Biotech Hunter | Biotech Hunter